T., Kukkonen-Harjula, T
Many patients who start with oral semaglutide due to insurance coverage eventually switch to compounded injectables when results disappoint
Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial
Specific Populations No clinically significant differences in semaglutide pharmacokinetics were observed based on age (18 years old), sex, race (White, Asian or Black or African American), ethnicity, body weight (40 to 188 kg), upper GI disease (i.e., chronic gastritis and/or gastroesophageal reflux disease), hepatic impairment (i.e., mild, moderate, severe based on the Child-Pugh system) and renal impairment (i.e., mild, moderate, severe, end staged renal disease)
Excited to see what month 2 has in store